January 28, 2020
This morning digital cardiac health startup Eko announced that its atrial fibrillation and heart murmur detection algorithm landed a 510(k) FDA clearance. The new algorithms are designed to integrate with Eko’s stethoscope, which is already on the market, and be used by healthcare providers.
The company said it plans to add more algorithms in the future. Next up will be an ECG-based algorithm...
December 19, 2019
ECG algorithm picks up Breakthrough Device status. Eko, the maker of tools for monitoring heart function, announced yesterday that a novel ECG-based algorithm for detecting lowered left ventricular ejection fraction has received Breakthrough Device designation from the FDA. By analyzing a 15-second clip of ECG data collected via the company’s other products, the algorithm aims to assist with...
November 26, 2019
Eko, the maker of devices and platforms for monitoring heart function, has announced the rollout of a second version of its CORE stethoscope that includes noise canceling capabilities and a sound amplifying feature.
Customers can buy the product as a digital attachment or an assembled stethoscope. The latest version will include a wireless connection to Eko’s software and a 10-hour battery. On...
November 22, 2019
There are few clinical areas more in need of innovation than heart disease. It’s the leading killer among men and women in the US, accounting for one in every four deaths by the CDC’s numbers, and yet it’s also a body of health conditions that could be substantially mitigated through a number of lifestyle and behavior changes.
So of course it’s little surprise that cardiovascular health and care...
November 19, 2019
Device regulation is a hurdle for any medical tech company, but doubly so for startups hoping to strike it big with their very first digital health product. With limited resources and experience, pushing a device through the FDA’s door and onto the market is a multi-year gauntlet of validation, documentation and, unfortunately, frustration.
To help young companies take a bit of the guesswork out...
September 25, 2019
Eko, maker of devices and platforms for monitoring heart function, has raised $20 million in Series B funding. The raise was led by ARTIS Ventures, and also includes DigiTx Partners, NTT Venture Capital (NTTVC), 3M Ventures, Mayo Clinic, Seaph Group and XTX Ventures.
Eko closed its previous rounds in February of last year and early 2015. Today’s announcement brings the company’s lifetime capital...
July 29, 2019
Last week, Eko Devices announced a new service that matches ECG and heart sound recordings with clinical data to help pinpoint novel drug-data combinations. The Silicon Valley startup is pitching the platform, called Eko Home, as a resource for clinical trials targeting new therapies.
The new platform is already seeing some action. According to the company, an ongoing Mayo Clinic study exploring...
October 25, 2018
The Mayo Clinic is joining forces with smart stethoscope company Eko to develop a new product that will employ machine learning and a digital stethoscope to assist doctors in detecting potentially dangerous heart conditions.
The pair plan to build a machine learning-based algorithm that can screen for a low ejection fraction, which means a weak heart pump in patients. The team developing the...
February 28, 2018
Berkeley, California-based smart stethoscope company Eko Devices has raised $5 million in new funding. Artis Ventures led the round, with additional participation from Strategic Partners, Dreamlt Ventures, 1812 Ventures, and Founder.org. This brings the company's funding up to $7.8 million — it last raised money in 2015.
Eko Devices received FDA clearance last year for Duo, a smart heart monitor...
June 7, 2017
Berkeley, California-based Eko Devices has received FDA clearance for Duo, a smart heart monitor that is a combination of a digital stethoscope and portable electrocardiogram.
Duo is intended as a prescription-only screening tool as part of an at-home monitoring plan, and it works with a companion app for remote monitoring or diagnosis. The idea is to keep continuous tabs on patients at risk for...